

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/133700 A2

- (51) **International Patent Classification:**
C07K 16/40 (2006.01) *A61P 25/14* (2006.01)
- (21) **International Application Number:**
PCT/IB2024/000732
- (22) **International Filing Date:**
20 December 2024 (20.12.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
20230101061 20 December 2023 (20.12.2023) GR
2400120.8 04 January 2024 (04.01.2024) GB
- (71) **Applicant:** **ALCHEMAB THERAPEUTICS LTD**
[GB/GB]; East Side Office 1.02, Kings Cross, London N1C 4AX (GB).
- (72) **Inventors:** **GASPARIUNAS, Aretas**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London N1C 4AX (GB). **MASON, Ashely, Jane**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London N1C 4AX (GB). **FINCH, Donna**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London N1C 4AX (GB). **LEWIS, Giles**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London N1C 4AX (GB).

tics Ltd, East Side Office 1.02, Kings Cross, London N1C 4AX (GB). **PEDIADITAKIS, Losif**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London N1C 4AX (GB). **DIAS DO NASCIMENTO, Jorge, Norman**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London N1C 4AX (GB). **SIDOR, Michelle**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London N1C 4AX (GB). **SNUDDEN, Olivia**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London N1C 4AX (GB). **KOLASINSKA-ZWIERZ, Paulina, Maria**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London N1C 4AX (GB). **YORUCU, Selda**; c/o Alchemab Therapeutics Ltd, East Side Office 1.02, Kings Cross, London N1C 4AX (GB).

(74) **Agent:** **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

(54) **Title:** ANTI-PGDH ANTIBODIES




Fig. 14A

(57) **Abstract:** Isolated antibodies which bind and inhibit 15-PGDH protein are described. Related nucleic acids, cells and therapeutic uses are also described.

[Continued on next page]

WO 2025/133700 A2

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*